February 12, 2026 a 08:38 am
ABBV: Analysts Ratings - AbbVie Inc.
AbbVie Inc. has been a notable player in the pharmaceutical industry with diverse offerings such as Humira and Rinvoq. Recent analyst ratings indicate a predominantly positive sentiment towards the company's performance, although there are subtle nuances in the market's perception that warrant further analysis. Understanding these ratings can provide valuable insights into potential market movements.
Historical Stock Grades
Examining recent rating data, we notice a stable outlook for AbbVie with a majority of analysts maintaining a "Buy" recommendation. The lack of "Sell" ratings suggests confidence, while the presence of one "Strong Sell" indicates some caution.
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 6 | |
| Buy | 13 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
The sentiment around AbbVie's stock has remained relatively stable over recent months. Despite slight fluctuations in the "Buy" ratings, the overall market perception has not significantly shifted towards negativity.
- December 2025 to January 2026: Consistent "Strong Buy" ratings with a stable core of "Buy" ratings.
- May to September 2025: Notable rise in "Hold" recommendations, indicating a more cautious stance by some analysts.
- February 2026: Introduction of a "Strong Sell" signal suggesting diverging opinions among analysts.
Percentage Trends
The percentage of "Buy" recommendations has decreased slightly from mid-2025, while "Hold" recommendations have increased. This points to a more cautious outlook by analysts, although "Strong Buy" recommendations remain stable.
- From July to November 2025, there was a decline in "Strong Buy" percentages, from 23% to 14%.
- In the same period, "Hold" increased from 40% to 46%, further indicating a cautious sentiment shift.
- Stable "Strong Buy" ratings with fluctuating "Buy" ratings suggest mixed market sentiments.
Latest Analyst Recommendations
Recent recommendations reflect a stable view on AbbVie with no major shifts in sentiment, except for a single downgrade.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-05 | Overweight | Overweight | Morgan Stanley |
| 2026-02-05 | Outperform | Outperform | Evercore ISI Group |
| 2026-02-05 | Neutral | Neutral | UBS |
| 2026-01-27 | Neutral | Neutral | Citigroup |
| 2026-01-08 | Peer Perform | Outperform | Wolfe Research |
Analyst Recommendations with Change of Opinion
Several analysts have updated their positions on AbbVie, reflecting a more cautious market view. Notably, Wolfe Research's downgrade in January signals increasing caution.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-08 | Peer Perform | Outperform | Wolfe Research |
| 2025-12-10 | Buy | Hold | HSBC |
| 2025-10-01 | Hold | Buy | HSBC |
| 2025-09-17 | Buy | Hold | Berenberg |
| 2025-05-14 | Neutral | Buy | Citigroup |
Interpretation
The recent analyst ratings suggest a stable yet cautiously optimistic market view on AbbVie, with a significant number of "Buy" and "Strong Buy" recommendations. The presence of a "Strong Sell" rating, along with a few downgrades, indicates some uncertainty in the market's outlook. However, the majority of recommendations remain positive, reflecting confidence in the company's fundamentals. Overall, the analyst sentiment remains firm with minor fluctuations, reflecting a balanced view of risks and opportunities.
Conclusion
In conclusion, AbbVie Inc.'s stock maintains a primarily positive perception among analysts, although growing caution is evident with the rise in "Hold" recommendations. The consistency of "Strong Buy" ratings highlights confidence in the company's future prospects. However, potential investors should remain mindful of the subtle shifts towards caution as denoted by the recent downgrades. Moving forward, monitoring analyst ratings and market reactions will be essential for a comprehensive understanding of AbbVie's position and potential for growth.